William Edward Boden, MD

Professor, Medicine

William Boden
150 South Huntington Avenue


I am ABIM board-certified in both Internal Medicine and the subspecialty of Cardiovascular Disease. Since 1979, I have held university appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, State University of New York in Buffalo, and Albany Medical College. For the past 27 consecutive years, I have held leadership roles as either a Chief of cardiology or Chief of Medicine at both federal VA facilities and in the academic private sector, all of which have had strong affiliations with their respective academic health centers. In 2016, I re-joined the VA Boston MAVERIC Center as the Scientific Director, Clinical Trials Network, for the VA New England Healthcare System, and as the Research Lead Physician, for VISN 1.

I have extensive prior experience in clinical trials and comparative effectiveness research, and have served in a leadership capacity in several important national and international clinical trials, including as Study Chair for VA CSP-funded VANQWISH and COURAGE Trials, as Study Co-Chair of the NIH-funded AIM-HIGH Trial, and as a national co-PI for the NIH-funded ISCHEMIA Trial. My principal research interests include studies in stable ischemic heart disease, post-MI secondary prevention, acute coronary syndromes, and preventive cardiology.

Other Positions

  • Lecturer in Medicine, Harvard Medical School
  • Physician Research Lead & Scientific Director, Clinical Trials Network, MAVERIC Center, VA Boston Healthcare System


  • State University of New York at Brockport, MD
  • Le Moyne College, BS


  • Published on 8/18/2021

    Boden WE, Caterina R, Taggart DP. Is there equivalence between PCI and CABG surgery in long-term survival of patients with diabetes? Importance of interpretation biases and biological plausibility. Eur Heart J. 2021 Aug 18. PMID: 34405227.

    Read at: PubMed
  • Published on 7/6/2021

    Boden WE, Gersh BJ. Defining the Proper SYNTAX for Long-Term Benefit of Myocardial Revascularization With Optimal Medical Therapy. J Am Coll Cardiol. 2021 07 06; 78(1):39-41. PMID: 34210412.

    Read at: PubMed
  • Published on 6/10/2021

    Brown DL, Boden WE. Impact of revascularisation on outcomes in chronic coronary syndromes: a new meta-analysis with the same old biases? Eur Heart J. 2021 Jun 10. PMID: 34110408.

    Read at: PubMed
  • Published on 5/4/2021

    Boden WE. RESPONSE: The Exit Interview-of a Professional Lifetime. J Am Coll Cardiol. 2021 May 04; 77(17):2256-2257. PMID: 33926662.

    Read at: PubMed
  • Published on 5/3/2021

    White HD, O'Brien SM, Alexander KP, Boden WE, Bangalore S, Li J, Manjunath CN, Lopez-Sendon JL, Peteiro J, Gosselin G, Berger JS, Maggioni AP, Reynolds HR, Hochman JS, Maron DJ. Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. JAMA Cardiol. 2021 May 03. PMID: 33938917.

    Read at: PubMed
  • Published on 4/19/2021

    Shah R, Nayyar M, Le FK, Labroo A, Nasr A, Rashid A, Davis DA, Weintraub WS, Boden WE. A meta-analysis of optimal medical therapy with or without percutaneous coronary intervention in patients with stable coronary artery disease. Coron Artery Dis. 2021 Apr 19. PMID: 33878073.

    Read at: PubMed
  • Published on 4/7/2021

    Gersh BJ, Boden WE, Bhatt DL, Stone PH, Crea F, L├╝scher TF. To stent or not to stent? Treating angina after ISCHEMIA-introduction. Eur Heart J. 2021 04 07; 42(14):1387-1388. PMID: 33827136.

    Read at: PubMed
  • Published on 4/7/2021

    Boden WE, Stone PH. To stent or not to stent? Treating angina after ISCHEMIA-why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial. Eur Heart J. 2021 04 07; 42(14):1394-1400. PMID: 33827137.

    Read at: PubMed
  • Published on 3/18/2021

    Handberg EM, Merz CNB, Cooper-Dehoff RM, Wei J, Conlon M, Lo MC, Boden W, Frayne SM, Villines T, Spertus JA, Weintraub W, O'Malley P, Chaitman B, Shaw LJ, Budoff M, Rogatko A, Pepine CJ. Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. Am Heart J. 2021 07; 237:90-103. PMID: 33745898.

    Read at: PubMed
  • Published on 2/9/2021

    McCreanor V, Nowbar A, Rajkumar C, Barnett AG, Francis D, Graves N, Boden WE, Weintraub WS, Al-Lamee R, Parsonage WA. Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial. BMJ Open. 2021 02 09; 11(2):e044054. PMID: 33563623.

    Read at: PubMed

View 334 more publications: View full profile at BUMC

View all profiles